Use of RPL41 to treat infections and inhibit cancer

Details Use of RPL41 to treat infections and inhibit cancer Use of RPL41 to treat infections and inhibit cancer

2007-02-27

2007-02-27

Gupta, Anish (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S324000

Reexamination Certificate

active

11105179

ABSTRACT:
The present invention relates to peptides of RPL41 and their use in the treatment of cancer and microbial infections. It is contemplated that modified forms of RPL41, including substitutional variants and mimetics, will be used. Mono- and combination therapies with other cancer treatments are contemplated.

REFERENCES:
patent: 2002/0051978 (2002-05-01), Roth et al.
Ahmed et al., “Significance of protein kinase CK1 nuclear signaling in neoplasia,”J. Cell Biochem. Suppl.,35:130-135, 2000.
Amsterdam et al., “Many ribosomal protein genes are cancer genes in zebrafish,”PLoS. Biol.,2:E139, 2004.
Becker-Hapak et al., “TAT-Mediated protein transduction into mammalian cells,”Methods,24:247-256, 2001.
Denicourt and Dowdy, “Protein transduction technology offers novel therapeutic approach for brain ischemia,”Trends Pharmacol. Sci.,24:216-218, 2003.
Faust et al., “Antinsense oligonucleotides against protein kinase CK2-a inhibit growth of squamous cell carcinoma of the head and neck in vitro,”Head Neck,22:341-346, 2000.
GenBank Accession No. AJ001347.
GenBank Accession No. NM—021104.
GenBank Accession No. X16066.
Go and Taniguchi, “Augmentation in the expression of a ribosomal protein associated with transformation,”Biochem. Mol. Biol. Int.,46(3):629-638, 1998.
Klaudiny et al., “Characterization by cDNA cloning of the mRNA of a highly basic human protein homologous to the yeast ribosomal protein YL41,”Biochem. Biophys. Res. Commun.,187(2):901-906, 1992.
Lee et al., “The highly basic ribosomal protein L41 interacts with the B subunit of protein kinase CKII and stimulates phosphorylation of DNA topoisomerase IIa by CKII,”Biochem. Biophys. Res. Commun.,238-(2):462-467, 1997.
Mutoh et al., “A gene coding for a ribosomal protein L41 in cycloheximide-resistant ribosomes has a promoter which is upregulated under the growth-inhibitory conditions in yeast, Candida maltosa,”Biochem. Biophys. Res. Commun.,258(3):611-615, 1999.
Schwarze et al., “Protein transduction: unrestricted delivery into all cells?,”Trends Cell Biol.,10:290-295, 2000.
Suzuki et al., “Yeast ribosomal proteins: XI> Molecular analysis of two genes encoding YL41, and extremely small basic ribosomal protein, fromSaccharomyces cerevisiae,” Curr. Genet.,17(3):185-190, 1990.
Tallada et al., “Genome-wide search of Schizosaccharomyces pombe genes causing overexpression-mediated cell cycle defects,”Yeast,19(13):1139-1151, 2002.
Wender et al., “The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters,”Proc. Natl. Acad. Sci. USA,97:13003-13008, 2000.
Woo and Hawes, “Cloning of genes whose expression is correlated with mitosis and localized in dividing cells in root caps of Pisum sativum L.,”Plant Mol. Biol.,35(6):1045-1051, 1997.
Yu and Warner,“Expression of a micro-protein,”J. Biol. Chem.,276(36);33821-33852, 2001.

Affiliated with

Also associated with

Rating

Use of RPL41 to treat infections and inhibit cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of RPL41 to treat infections and inhibit cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of RPL41 to treat infections and inhibit cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3866398